AbbVie's zumilokibart clears Phase II with long-interval dosing signal
AbbVie reports its injectable biologic zumilokibart cleared Phase II, with a profile the company says could support quarterly or twice-yearly maintenance dosing.
Topic
Abbvie
Topic
Abbvie
Zumilokibart Hits EASI-75 Endpoint in Phase 2 AD Trial
All three zumilokibart dose regimens beat placebo on EASI-75 at Week 16 in the Phase 2 APEX Part B study of moderate-to-severe at…
AbbVie Moves Zumilokibart Into Phase 3 Atopic Dermatitis Trials
AbbVie advances its IL-13-targeting biologic zumilokibart into Phase 3 atopic dermatitis trials, adding a pipeline candidate alon…
Zumilokibart Hits EASI-75 Primary Endpoint in Phase 2 Atopic Dermatitis Trial
AbbVie's zumilokibart met its EASI-75 primary endpoint in the 346-patient Phase 2 APEX Part B study, with the mid-dose regimen ad…
AbbVie Brings 60 Dermatology Abstracts to 2026 EADV Congress
AbbVie will present 60 dermatology abstracts at the 2026 EADV Congress, one of the largest industry research footprints planned f…
AbbVie Reports Positive Phase 2 APEX Part B Results for Zumilokibart
AbbVie presented positive Phase 2 APEX Part B results for the IL-13 inhibitor zumilokibart in moderate to severe atopic dermatiti…
AbbVie's zumilokibart Hits Phase 2 Atopic Dermatitis Endpoint
AbbVie reports zumilokibart met its primary endpoint in a phase 2 atopic dermatitis trial, advancing a key pipeline asset toward…